Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Castle Biosciences (Nasdaq:CSTL) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4). On June 15, 2026, its Compensation Committee granted RSUs covering 204,925 shares of common stock to 172 new employees under the 2022 Inducement Plan, vesting over four years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Inducement RSUs covering 204,925 shares granted to attract 172 new employees
• Four-year vesting schedule supports long-term employee retention and alignment with shareholders

Negative

• RSUs covering 204,925 shares may increase share count and dilute existing shareholders

What This Means

This announcement details RSU inducement grants covering 204,925 shares for 172 new employees, vesti...

Analysis

This announcement details RSU inducement grants covering 204,925 shares for 172 new employees, vesting over four years. It adds structured equity-based hiring incentives alongside recent insider net selling and a relatively low short‑interest backdrop.

Key Figures

Employees receiving RSUs: 172 employees RSU share total: 204,925 shares Grant date: June 15, 2026 +3 more

6 metrics

Employees receiving RSUs 172 employees Inducement equity grants announced June 19, 2026

RSU share total 204,925 shares Aggregate common stock underlying inducement RSUs

Grant date June 15, 2026 Compensation Committee approval of inducement RSUs

Initial vesting 25% after 1 year First tranche of inducement RSUs

Vesting period 4 years Total vesting schedule for inducement RSUs

Follow-on vesting 3 equal annual installments Remaining RSU vesting after first anniversary

Historical Context

5 past events · Latest: Jun 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 16	Product usage milestone	Positive	-1.0%	TissueCypher Barrett's Esophagus test surpassing 100,000 cumulative clinical orders.
May 13	Conference participation	Neutral	-2.6%	Announcement of management presentation at Jefferies Global Healthcare Conference.
May 12	Innovation award	Positive	-2.1%	AdvanceAD-Tx test receiving 2026 MedTech Breakthrough Genomics Innovation Award.
May 06	Quarterly earnings	Positive	-22.3%	Q1 2026 results with revenue reported and full-year guidance raised.
May 05	Awareness initiatives	Positive	-3.6%	Support for nationwide advocacy and screening during Skin Cancer Awareness Month.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Over the last several months, CSTL has often traded lower following generally positive or neutral news events, indicating a tendency toward divergence between headlines and price reaction.

Regulatory & Risk Context

Short Interest: 5.26%

Short Interest

5.26% of float

0% 15% 30%+

low as of 2026-05-29 Days to cover: 3.78

Short interest is relatively low, suggesting limited short‑squeeze potential and a more moderate contribution to day‑to‑day share price volatility under normal trading conditions.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement plan

4 terms

restricted stock units financial

"granted restricted stock units (RSUs) to 172 employees covering an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"The RSUs were granted pursuant to the Company's 2022 Inducement Plan"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 172 employees covering an aggregate of 204,925 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee's continued service through each applicable vesting date.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302804688.html

SOURCE Castle Biosciences, Inc.

FAQ

What did Castle Biosciences (NASDAQ:CSTL) announce on June 19, 2026?

Castle Biosciences announced inducement restricted stock unit grants to new employees. According to Castle Biosciences, its Compensation Committee approved RSUs covering 204,925 common shares for 172 employees on June 15, 2026, under the 2022 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).

How many Castle Biosciences (CSTL) shares are covered by the new inducement RSUs?

The new inducement RSUs cover 204,925 shares of Castle Biosciences common stock. According to Castle Biosciences, these awards were granted to 172 employees as a material inducement to join the company, under its 2022 Inducement Plan, and follow Nasdaq Listing Rule 5635(c)(4).

What is the vesting schedule for Castle Biosciences (CSTL) inducement RSUs granted June 15, 2026?

The inducement RSUs vest over four years. According to Castle Biosciences, 25% of each award vests on the first anniversary of the vesting commencement date, with the remaining 75% vesting in three equal annual installments, subject to continued employee service.

Why did Castle Biosciences grant RSUs under Nasdaq Listing Rule 5635(c)(4)?

Castle Biosciences used RSUs as a material inducement for new hires. According to Castle Biosciences, the 204,925-share RSU grants to 172 employees were issued under its 2022 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4) for employment-related equity awards.

How many employees received Castle Biosciences (CSTL) inducement RSUs in June 2026?

A total of 172 employees received inducement RSUs from Castle Biosciences. According to Castle Biosciences, these employees were granted restricted stock units covering an aggregate of 204,925 common shares as a condition of entering employment, with vesting spread across four years.